The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Evidence of Artemisinin-Resistant Malaria in Africa
Open accessAbstract
BACKGROUNDIn the six Southeast Asian countries that make up the Greater Mekong Subregion, Plasmodium falciparum has developed resistance to derivatives of artemisinin, the main component of first-line treatments for malaria.Clinical resistance to artemisinin monotherapy in other global regions, including Africa, would be problematic. METHODSIn this longitudinal study conducted in Northern Uganda, we treated patients who had P. falciparum infection with intravenous artesunate (a water-soluble artemisinin derivative) and estimated the parasite clearance half-life.We evaluated ex vivo susceptibility of the parasite using a ring-stage survival assay and genotyped resistancerelated genes. RESULTSFrom 2017 through 2019, a total of 14 of 240 patients who received intravenous artesunate had evidence of in vivo artemisinin resistance (parasite clearance halflife, >5 hours).Of these 14 patients, 13 were infected with P. falciparum parasites with mutations in the A675V or C469Y allele in the kelch13 gene.Such mutations were associated with prolonged parasite clearance half-lives (geometric mean, 3.95 hours for A675V and 3.30 hours for C469Y, vs. 1.78 hours for wild-type allele; P<0.001 and P = 0.05, respectively).The ring-stage survival assay showed a higher frequency of parasite survival among organisms with the A675V allele than among those with the wild-type allele.The prevalence of parasites with kelch13 mutations increased significantly, from 3.9% in 2015 to 19.8% in 2019, due primarily to the increased frequency of the A675V and C469Y alleles (P<0.001 and P = 0.004, respectively).Single-nucleotide polymorphisms flanking the A675V mutation in Uganda were substantially different from those in Southeast Asia. CONCLUSIONSThe independent emergence and local spread of clinically artemisinin-resistant P. falciparum has been identified in Africa.The two kelch13 mutations may be markers for detection of these resistant parasites.(Funded by the Japan Society for the Promotion of Science and others.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language for Data Analysis and Graphics
Ihaka, R., & Gentleman, R. (1996) · Journal of Computational and Graphical Statistics · doi:10.1080/10618600.1996.10474713 · Cited by 11,220
Artemisinin Resistance in Plasmodium falciparum Malaria
Dondorp, A. M., Nosten, F., Yi, P., Das, D., Phyo, A. P., Tarning, J., Lwin, K. M., Ariey, F., Hanpithakpong, W., Lee, S. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808859 · Cited by 3,424
The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015
Bhatt, S., Weiss, D. J., Cameron, E., Bisanzio, D., Mappin, B., Dalrymple, U., Battle, K. E., Moyes, C. L., Henry, A., Eckhoff, P. A., et al. (2015) · Nature · doi:10.1038/nature15535 · Cited by 3,225
Spread of Artemisinin Resistance in Plasmodium falciparum Malaria
Ashley, E. A., Dhorda, M., Fairhurst, R. M., Amaratunga, C., Lim, P., Suon, S., Sreng, S., Anderson, J. M., Mao, S., Sam, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314981 · Cited by 2,205
A molecular marker of artemisinin-resistant Plasmodium falciparum malaria
Ariey, F., Witkowski, B., Amaratunga, C., Beghain, J., Langlois, A.-C., Khim, N., Kim, S., Duru, V., Bouchier, C., Ma, L., et al. (2014) · Nature · doi:10.1038/nature12876 · Cited by 2,090
Uwimana, A., Legrand, E., Stokes, B. H., Ndikumana, J.-L. M., Warsame, M., Umulisa, N., Ngamije, D., Munyaneza, T., Mazarati, J.-B., Munguti, K., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1005-2 · Cited by 831
Witkowski, B., Amaratunga, C., Khim, N., Sreng, S., Chim, P., Kim, S., Lim, P., Mao, S., Sopha, C., Sam, B., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70252-4 · Cited by 629
Genetic architecture of artemisinin-resistant Plasmodium falciparum
Miotto, O., Amato, R., Ashley, E. A., MacInnis, B., Almagro-Garcia, J., Amaratunga, C., Lim, P., Mead, D., Oyola, S. O., Dhorda, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3189 · Cited by 609
Parasitologic and Clinical Human Response to Immunoglobulin Administration in Falciparum Malaria
Sabchareon, A., Burnouf, T., Ouattara, D., Attanath, P., Bouharoun-Tayoun, H., Chantavanich, P., Foucault, C., Chongsuphajaisiddhi, T., & Druilhe, P. (1991) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1991.45.297 · Cited by 499
Uwimana, A., Umulisa, N., Venkatesan, M., Svigel, S. S., Zhou, Z., Munyaneza, T., Habimana, R. M., Rucogoza, A., Moriarty, L. F., Sandford, R., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00142-0 · Cited by 435
van der Pluijm, R. W., Imwong, M., Chau, N. H., Hoa, N. T., Thuy-Nhien, N. T., Thanh, N. V., Jittamala, P., Hanboonkunupakarn, B., Chutasmit, K., Saelow, C., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30391-3 · Cited by 386
Amaratunga, C., Sreng, S., Suon, S., Phelps, E. S., Stepniewska, K., Lim, P., Zhou, C., Mao, S., Anderson, J. M., Lindegardh, N., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70181-0 · Cited by 344
WWARN K13 Genotype-Phenotype Study Group (2019) · BMC Medicine · doi:10.1186/s12916-018-1207-3 · Cited by 320
Genomic epidemiology of artemisinin resistant malaria
MalariaGEN Plasmodium falciparum Community Project (2016) · eLife · doi:10.7554/elife.08714 · Cited by 297
Flegg, J. A., Guerin, P. J., White, N. J., & Stepniewska, K. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-339 · Cited by 285
Artemisinin-Resistant Malaria in Asia
Noedl, H., Socheat, D., & Satimai, W. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0900231 · Cited by 267
Emergence of Indigenous Artemisinin-Resistant Plasmodium falciparum in Africa
Lu, F., Culleton, R., Zhang, M., Ramaprasad, A., von Seidlein, L., Zhou, H., Zhu, G., Tang, J., Liu, Y., Wang, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1612765 · Cited by 266
Antimalarial drug resistance in Africa: the calm before the storm?
Conrad, M. D., & Rosenthal, P. J. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30261-0 · Cited by 255
White, N. J. (2017) · Malaria Journal · doi:10.1186/s12936-017-1731-1 · Cited by 230
Malaria in Uganda: Challenges to control on the long road to elimination
Yeka, A., Gasasira, A., Mpimbaza, A., Achan, J., Nankabirwa, J., Nsobya, S., Staedke, S. G., Donnelly, M. J., Wabwire-Mangen, F., Talisuna, A., et al. (2012) · Acta Tropica · doi:10.1016/j.actatropica.2011.03.004 · Cited by 210
Asua, V., Conrad, M. D., Aydemir, O., Duvalsaint, M., Legac, J., Duarte, E., Tumwebaze, P., Chin, D. M., Cooper, R. A., Yeka, A., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa687 · Cited by 203
Artemisinin-Resistant Plasmodium falciparum with High Survival Rates, Uganda, 2014–2016
Ikeda, M., Kaneko, M., Tachibana, S.-I., Balikagala, B., Sakurai-Yatsushiro, M., Yatsushiro, S., Takahashi, N., Yamauchi, M., Sekihara, M., Hashimoto, M., et al. (2018) · Emerging Infectious Diseases · doi:10.3201/eid2404.170141 · Cited by 161
Self-citationMiotto, O., Sekihara, M., Tachibana, S., Yamauchi, M., Pearson, R. D., Amato, R., Gonçalves, S., Mehra, S., Noviyanti, R., Marfurt, J., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1009133 · Cited by 152
Self-citationHuang, F. J., Takala‐Harrison, S., Jacob, C. G., Liu, H., Sun, X., Yang, H., Nyunt, M. M., Adams, M., Zhou, S., Xia, Z., et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv249 · Cited by 149
Talundzic, E., Okoth, S. A., Congpuong, K., Pluciński, M. M., Morton, L. C., Goldman, I. F., Kachur, S. P., Wongsrichanalai, C., Satimai, W., Barnwell, J. W., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004789 · Cited by 119
Siddiqui, F. A., Boonhok, R., Cabrera, M., Mbenda, H. G. N., Wang, M., Min, H., Liang, X., Qin, J., Zhu, X., Miao, J., et al. (2020) · mBio · doi:10.1128/mbio.01134-19 · Cited by 100
Acquisition of Growth-Inhibitory Antibodies against Blood-Stage Plasmodium falciparum
McCallum, F. J., Persson, K. E. M., Mugyenyi, C. K., Fowkes, F. J. I., Simpson, J. A., Richards, J. S., Williams, T. N., Marsh, K., & Beeson, J. G. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003571 · Cited by 98
Spatial-temporal patterns of malaria incidence in Uganda using HMIS data from 2015 to 2019
Kigozi, S. P., Kigozi, R. N., Sebuguzi, C. M., Cano, J., Rutazaana, D., Opigo, J., Bousema, T., Yeka, A., Gasasira, A. F., Sartorius, B. K. D., et al. (2020) · BMC Public Health · doi:10.1186/s12889-020-10007-w · Cited by 90
Kayiba, N. K., Yobi, D. M., Tshibangu‐Kabamba, E., Tuan, V. P., Yamaoka, Y., Devleesschauwer, B., Mvumbi, D. M., Wemakoy, E. O., Mol, P. D., Mvumbi, G. L., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30493-x · Cited by 77
Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda
Asua, V., Vinden, J., Conrad, M. D., Legac, J., Kigozi, S. P., Kamya, M. R., Dorsey, G., Nsobya, S. L., & Rosenthal, P. J. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01818-18 · Cited by 76
Slow Clearance ofPlasmodium falciparumin Severe Pediatric Malaria, Uganda, 2011–2013
Hawkes, M., Conroy, A. L., Opoka, R. O., Namasopo, S., Zhong, K., Liles, W. C., John, C. C., & Kain, K. C. (2015) · Emerging infectious diseases · doi:10.3201/eid2107.150213 · Cited by 63
Defining the In Vivo Phenotype of Artemisinin-Resistant Falciparum Malaria: A Modelling Approach
White, L. J., Flegg, J. A., Phyo, A. P., Wiladpai-ngern, J. H., Bethell, D., Plowe, C. V., Anderson, T., Nkhoma, S. C., Nair, S., Tripura, R., et al. (2015) · PLoS Medicine · doi:10.1371/journal.pmed.1001823 · Cited by 43
Complexity ofPlasmodium falciparumInfections and Antimalarial Drug Efficacy at 7 Sites in Uganda
Lee, S. A., Yeka, A., Nsobya, S. L., Dokomajilar, C., Rosenthal, P. J., Talisuna, A. O., & Dorsey, G. (2006) · The Journal of Infectious Diseases · doi:10.1086/501473 · Cited by 39
Absence of in vivo selection for K13 mutations after artemether–lumefantrine treatment in Uganda
Balikagala, B., Mita, T., Ikeda, M., Sakurai, M., Yatsushiro, S., Takahashi, N., Tachibana, S., Auma, M. A., Ntege, E. H., Ito, D., et al. (2017) · Malaria Journal · doi:10.1186/s12936-016-1663-1 · Cited by 36
Self-citation
Cited by
Emiru, T., Getachew, D., Murphy, M., Sedda, L., Ejigu, L. A., Bulto, M. G., Byrne, I., Demisse, M., Abdo, M., Chali, W., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02641-9 · Cited by 162
Anopheles stephensi in Africa requires a more integrated response
Mnzava, A., Monroe, A. C., & Okumu, F. (2022) · Malaria Journal · doi:10.1186/s12936-022-04197-4 · Cited by 95
“The other important biological concerns include: (a) the widespread resistance of malaria vectors to public health insecticides, notably those used for insecticide treated nets (ITNs) and indoor residual spraying (IRS) [11]; (b) the emerging threat of parasite resistance to frontline malaria treatments [12, 13] and (c…”
BackgroundQiu, D., Pei, J. V., Rosling, J. E. O., Thathy, V., Li, D., Xue, Y., Tanner, J. D., Penington, J. S., Aw, Y. T. V., Aw, J. Y. H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33403-9 · Cited by 70
Nayak, S., Peto, T. J., Kucharski, M., Tripura, R., Callery, J. J., Quang Huy, D. T., Gendrot, M., Lek, D., Nghia, H. D. T., van der Pluijm, R. W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54915-6 · Cited by 15
Leaving no one behind: the need for a truly global response to antimicrobial resistance
Goldberg, J., Clezy, K., Jasovský, D., & Uyen-Cateriano, A. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00303-7 · Cited by 8
Metadata
- Authors
- Balikagala, B., Fukuda, N., Ikeda, M., Katuro, O. T., Tachibana, S.-I., Yamauchi, M., Opio, W., Emoto, S., Anywar, D. A., Kimura, E., Palacpac, N. M. Q., Odongo-Aginya, E. I., Ogwang, M., Horii, T., & Mita, T.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-09-23
- Volume
- 385
- Issue
- 13
- Pages
- 1163-1171
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3200040377
- Cited by
- 866
- References
- 34
- FWCI
- 119.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.